机构：[1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China[2]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China[3]Beijing Hospital, National Geriatric Medical Center, Beijing, China[4]The Afliated Provincial Hospital of Anhui Medical University, Hefei, Anhui, China[5]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[6]Second Afliated Hospital of Nanchang University, Nanchang, China[7]Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Zhejiang, China浙江省肿瘤医院[8]Shanxi Cancer Hospital and the Afliated Cancer Hospital of Shanxi Medical University, Taiyuan, Shanxi, China[9]Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China[10]Afliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang, Guizhou, China[11]Hunan Cancer Hospital and the Afliated Cancer Hospital of Xiangya School of Medicine, Changsha, Hunan, China[12]Xijing Hospital of Fourth Military Medical University, Xi’an, China[13]Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin, China[14]The Fifth Medical Center of PLA General Hospital, Beijing, China[15]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China[16]Sun Yat-sen University Cancer Center.State Key Laboratory of Oncology in South China.Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China[17]Chongqing University Cancer Hospital & Chongqing Cancer Hospital, Chongqing, China[18]Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China[19]Union Hospital, Tongji Medical College, Huazhong.University of Science and Technology, Wuhan, Hubei, China华中科技大学同济医学院附属协和医院[20]The General Hospital of Chinese People’s Liberation Army, Beijing, China[21]Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China[22]Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2013, USA
Recently, progression-free survival at 24 months (PFS24) was defined as clinically relevant for patients with extranodal NK/T cell lymphoma. Herein, the clinical data from two independent random cohorts (696 patients each in the primary and validation datasets) were used to develop and validate a risk index for PFS24 (PFS24-RI), and evaluate its ability to predict early progression. Patients achieving PFS24 had a 5-year overall survival (OS) of 95.8%, whereas OS was only 21.2% in those failing PFS24 (P<0.001). PFS24 was an important predictor of subsequent OS, independent of risk stratification. The proportion of patients achieving PFS24 and 5-year OS rates correlated linearly among risk-stratified groups. Based on multivariate analysis of the primary dataset, the PFS24-RI included five risk factors: stage II or III/IV, elevated lactate dehydrogenase, Eastern Cooperative Oncology Group score >= 2, primary tumor invasion, and extra-upper aerodigestive tract. PFS24-RI stratified the patients into low-risk (0), intermediate-risk (1-2), high-risk (>= 3) groups with different prognoses. Harrell's C-index of PFS24-RI for PFS24 prediction was 0.667 in the validation dataset, indicating a good discriminative ability. PFS24-RI calibration indicated that the actual observed and predicted probability of failing PFS24 agreed well. PFS24-RI provided the probability of achieving PFS24 at an individual patient level.
基金：
National Key Research and Development of China [2020AAA0109504]; National Natural Science Foundation of China [81970185]
第一作者机构：[1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Jia‑Ying Li,Xiao‑Rong Hou,Si‑Ye Chen,et al.Outcome and risk prediction of early progression in patients with extranodal natural killer/T cell lymphoma from the CLCG study[J].ANNALS OF HEMATOLOGY.2023,102(9):2459-2469.doi:10.1007/s00277-023-05311-5.
APA：
Jia‑Ying Li,Xiao‑Rong Hou,Si‑Ye Chen,Xin Liu,Qiu‑Zi Zhong...&Ye‑Xiong Li.(2023).Outcome and risk prediction of early progression in patients with extranodal natural killer/T cell lymphoma from the CLCG study.ANNALS OF HEMATOLOGY,102,(9)
MLA：
Jia‑Ying Li,et al."Outcome and risk prediction of early progression in patients with extranodal natural killer/T cell lymphoma from the CLCG study".ANNALS OF HEMATOLOGY 102..9(2023):2459-2469
